HC Wainwright Estimates Liquidia’s Q3 Earnings (NASDAQ:LQDA)

Liquidia Corporation (NASDAQ:LQDA) – HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for shares of Liquidia in a research note issued to investors on Friday, October 2nd. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.76 per share for the quarter, down from their prior forecast of $1.01. HC Wainwright currently has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is $2.10 per share. HC Wainwright also issued estimates for Liquidia’s Q4 2026 earnings at $0.70 EPS, FY2026 earnings at $2.72 EPS, FY2027 earnings at $4.00 EPS, FY2028 earnings at $4.49 EPS, FY2029 earnings at $5.29 EPS and FY2030 earnings at $6.14 EPS.

Several other brokerages also recently issued reports on LQDA. BTIG Research downgraded shares of Liquidia from a “buy” rating to a “neutral” rating in a research report on Thursday, October 1st. Raymond James Financial cut shares of Liquidia from a “strong-buy” rating to an “outperform” rating and reduced their target price for the company from $106.00 to $53.00 in a report on Thursday, October 1st. Needham & Company LLC decreased their target price on shares of Liquidia from $110.00 to $72.00 and set a “buy” rating for the company in a research note on Thursday, October 1st. Citigroup reissued a “neutral” rating on shares of Liquidia in a report on Thursday, October 1st. Finally, Lifesci Capital cut Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Liquidia Stock Down 6.3%

LQDA stock opened at $25.91 on Tuesday. The company has a market cap of $2.32 billion, a price-to-earnings ratio of 18.91 and a beta of 0.61. The company has a fifty day moving average price of $69.27 and a 200 day moving average price of $62.07. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. Liquidia has a 12 month low of $21.94 and a 12 month high of $93.61.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period last year, the firm earned ($0.49) EPS. The company’s quarterly revenue was up 1842.1% on a year-over-year basis.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its stake in shares of Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares in the last quarter. Eversept Partners LP boosted its stake in shares of Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after buying an additional 167,949 shares in the last quarter. Pale Fire Capital SE boosted its stake in shares of Liquidia by 2.4% in the first quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock valued at $14,657,000 after buying an additional 8,985 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Liquidia during the second quarter worth $29,694,000. Finally, Seven Fleet Capital Management LP grew its holdings in Liquidia by 25.2% during the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after acquiring an additional 51,727 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Activity at Liquidia

In other news, insider Jason Adair sold 73,631 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $69.09, for a total value of $5,087,165.79. Following the completion of the sale, the insider owned 174,606 shares in the company, valued at approximately $12,063,528.54. This trade represents a 29.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephen Bloch sold 100,000 shares of Liquidia stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $89.48, for a total transaction of $8,948,000.00. Following the completion of the sale, the director directly owned 501,477 shares in the company, valued at approximately $44,872,161.96. The trade was a 16.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 522,519 shares of company stock worth $40,040,514 in the last 90 days. Corporate insiders own 25.60% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $58 price target, substantially above recent trading levels. The analyst still projects Liquidia will remain profitable, with estimated EPS of $2.72 in fiscal 2026 rising to $6.14 by 2030. HC Wainwright Estimates Liquidia’s Q3 Earnings
• Neutral Sentiment: HC Wainwright lowered its estimates for third-quarter 2026 EPS to $0.76 from $1.01 and fourth-quarter EPS to $0.70 from $1.18. The firm also reduced its full-year forecasts through 2030, but its long-term estimates still imply earnings growth and remain above the current-year consensus estimate of $2.34 per share. Liquidia earnings estimate revisions
• Negative Sentiment: A federal court found that two United Therapeutics patent claims were valid and infringed by YUTREPIA’s use in pulmonary hypertension associated with interstitial lung disease. Liquidia plans to remove that indication from the product label, raising concerns about potential limits on availability and the company’s previously projected revenue growth. Liquidia Falls as Patent Ruling Overhang Continues
• Negative Sentiment: Levi & Korsinsky announced an investigation into whether Liquidia properly disclosed risks related to the patent ruling and its forecast of more than $1 billion in 2027 net revenue. The legal uncertainty is particularly material because YUTREPIA generated approximately $170.4 million in second-quarter net product sales. Liquidia Investigation Notice
• Negative Sentiment: Reported insider activity has been heavily weighted toward sales, including transactions by senior executives, adding another source of investor caution.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).